Table 2.
Comparison of clinical features in patients with complete, partial, and no remission after tacrolimus treatment
| Items | No Remission N = 137 |
Partial remission N = 176 |
Complete remission N = 95 |
P-value |
|---|---|---|---|---|
| Age | 40 ± 16 | 38 ± 16 | 37 ± 15 | 0.31 |
| Gender (Female %) | 21.2% | 21.6% | 45.3% | <0.001 |
| eGFR (mL/min/1.73 m2) | 100 ± 28 | 107 ± 23 | 111 ± 22 | 0.008 |
| eGFR < 60 mL/min/1.73 m2 | 6.6% | 2.3% | 2.1% | 0.11 |
| Proteinuria, g/24 h | 6.4 (4.7–8.4) | 6.1(4.8–7.9) | 5.9 (4.7–7.4) | 0.37 |
| Serum albumin (g/L) | 24.2 ± 3.4 | 24.7 ± 3.3 | 24.8 ± 3.4 | 0.30 |
| Previous treatment with immunosuppressive drugs | 26.3% | 14.7 | 9.5% | 0.002 |
| Combined with RASi treatment | 68.6% | 71.5% | 66.3% | 0.65 |
| Combined with corticosteroids | 90.5% | 94.9% | 96.8% | 0.11 |
| Tacrolimus treatment since onset of disease (months) | 7.6 (3.9–14.8) | 7.3 (2.9–13.3) | 5.1 (2.1–9.5) | 0.001 |
| Tacrolimus exposure (ng/mL) | 4.2 ± 2.0 | 4.7 ± 2.1 | 5.2 ± 2.2 | 0.002 |